EUVIMEDEUVIMED entdecken
Open Access · CC0

Transport of CCL2 across an induced pluripotent stem cell-derived in vitro model of the human blood-brain barrier is heparan sulfate-dependent

Lindsey M Williams iD, Takashi Fujimoto, Mamatha Damodarasamy, Riley R Weaver, C Dirk Keene, William A Banks, May J Reed, Michelle A Erickson iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0338780 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Lindsey M Williams und 7 weiteren Autor:innen. Beteiligte Einrichtung: Geriatric Research Education and Clinical Center (GRECC), VA Puget Sound Healthcare System, Seattle, Washington, United States of America. Hauptthemen laut MEDLINE: Blood-Brain Barrier, Heparan Sulfate, Induced Pluripotent Stem Cells, Chemokine CCL2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: NIA NIH HHS, NINDS NIH HHS, Veterans Affairs Puget Sound Health Care System Director’s Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transport of immune-active substances across the blood-brain barrier (BBB) is an important mechanism of neuroimmune regulation. CCL2 is an exemplary chemokine that regulates neuroinflammation and can cross the intact BBB from blood to brain in mice. This study aimed to characterize the blood-to-brain transport mechanisms of human CCL2 using human induced pluripotent stem cell (iPSC)-derived brain endothelial-like cells (iBECs), an in vitro BBB model. Since heparan sulfate (HS) is an important component of the in vivo BBB that regulates CCL2 transport in mice, we first assessed HS deposition in iBECs and found that HS levels increased with extended culture time. We therefore evaluated transport of radiolabeled 125 I-CCL2 and 131 I-BSA after nine days in subculture, after HS had sufficient time to accumulate. To determine the predominant transport mechanism in vitro , we evaluated whether transport of 125 I-CCL2 and 131 I-BSA was altered in the presence of an inhibitor of the chemokine receptor CCR2, and following treatment with heparin, heparinase enzymes, or the heparan sulfate synthesis inhibitor GalNaz which all test HS-dependent mechanisms of transport. We also evaluated the expression of CCR2 and membrane-bound HS proteoglycans (HSPGs) in iBECs and in isolated human brain microvessels. We found that iBECs have a functional blood-to-brain transport system for CCL2. Similar to findings in mice, heparin inhibited CCL2 transport whereas the CCR2 inhibition did not. Both heparinase treatment and treatment with GalNaz inhibited CCL2 transport across the BBB, further supporting the involvement of HS in CCL2 transport. The iBECs expressed CCR2 at levels comparable to human brain microvessels, and had detectable expression of the syndecans 1–4 and glypicans 1–6, whereas human brain microvessels expressed syndecans 2–4 and glypicans 2–5 in all subjects tested. Our findings highlight that iBECs are a useful tool for studying the involvement of heparan sulfate/glycocalyx components in the transport of substances across the BBB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood-Brain BarrierHeparan SulfateInduced Pluripotent Stem CellsChemokine CCL2HumansEndothelial CellsBiological TransportAnimalsMiceReceptors, CCR2Brain

Substanzen

Heparan SulfateChemokine CCL2Receptors, CCR2CCL2 protein, human

Autor:innen und Institutionen

  • Geriatric Research Education and Clinical Center (GRECC), VA Puget Sound Healthcare System, Seattle, Washington, United States of America.
  • Department of Pharmaceutics, University of Washington School of Pharmacy, Seattle, Washington, United States of America.
  • Department of Neurosurgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Department of Medicine, Division of Gerontology and Geriatric Medicine, University of Washington School of Medicine, Seattle, Washington, United States of America.
  • Department of Laboratory Medicine and Pathology, Division of Neuropathology, University of Washington, Seattle, Washington, United States of America.

ORCID-Profile: Lindsey M Williams, Michelle A Erickson

Förderung

  • NIA NIH HHS
  • NINDS NIH HHS
  • Veterans Affairs Puget Sound Health Care System Director’s Fund
  • Joe W. and Dorothy Dorsett Brown Foundation
  • NIH
  • National Institutes of Health
  • Adult Changes in Thought (ACT) study
  • BRAIN Initiative Cell Atlas Network

Zitieren

APA

Williams, L. M., Fujimoto, T., Damodarasamy, M., Weaver, R. R., Keene, C. D., Banks, W. A., Reed, M. J., & Erickson, M. A. (2025). Transport of CCL2 across an induced pluripotent stem cell-derived in vitro model of the human blood-brain barrier is heparan sulfate-dependent. PLOS One. https://doi.org/10.1371/journal.pone.0338780

Vancouver

Williams LM, Fujimoto T, Damodarasamy M, Weaver RR, Keene CD, Banks WA, et al. Transport of CCL2 across an induced pluripotent stem cell-derived in vitro model of the human blood-brain barrier is heparan sulfate-dependent. PLOS One. 2025. doi:10.1371/journal.pone.0338780

BibTeX
@article{Williams2025,
  author = {Williams, Lindsey M and Fujimoto, Takashi and Damodarasamy, Mamatha and Weaver, Riley R and Keene, C Dirk and Banks, William A and Reed, May J and Erickson, Michelle A},
  title = {Transport of CCL2 across an induced pluripotent stem cell-derived in vitro model of the human blood-brain barrier is heparan sulfate-dependent},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0338780}
}
Kostenlos starten →